Our Pricing

Wegovy vs Mounjaro: Appetite Suppression Timeline Compared

Published on: June 03, 2026

Understanding the wegovy vs mounjaro appetite suppression timeline is crucial when choosing between these two leading weight loss treatments. At Cured Pharmacy, our UK-registered clinical team assesses hundreds of patients monthly, and the most common question we receive is how quickly each medication begins to control hunger. Both Wegovy (semaglutide) and Mounjaro (tirzepatide) work by mimicking natural gut hormones that regulate appetite, but their timelines and mechanisms differ in clinically significant ways.

How Quickly Does Wegovy Suppress Appetite?

Wegovy contains semaglutide, a GLP-1 receptor agonist that activates receptors in the brain's appetite control centres and slows gastric emptying [1]. Most patients report noticeable appetite reduction within 3 to 5 days of their first injection, though the effect strengthens progressively as the dose escalates over 16 weeks.

In the STEP clinical trial programme, participants experienced significant reductions in hunger scores within the first week of treatment, with peak appetite suppression occurring after 8 to 12 weeks on the maintenance dose [1]. The gradual dose escalation protocol — starting at 0.25mg weekly and increasing to 2.4mg — allows your body to adapt whilst minimising gastrointestinal side effects.

Clinical observations from our prescribing team at Cured Pharmacy show that approximately 70% of patients notice reduced portion sizes and fewer cravings within the first fortnight, particularly a decreased interest in high-fat and sugary foods. The appetite-suppressing effects typically persist for 5 to 6 days after each weekly injection, providing consistent hunger control throughout the week [2].

Wegovy Appetite Suppression: Week-by-Week Timeline

Week 1-4 (0.25mg dose): Mild to moderate appetite reduction, particularly noticeable after meals. Some patients report feeling fuller sooner when eating.

Week 5-8 (0.5mg-1mg doses): More pronounced hunger suppression between meals. Cravings for energy-dense foods typically diminish during this phase.

Week 9-16 (1.7mg-2.4mg doses): Peak appetite control achieved. Most patients report substantially smaller portion sizes and prolonged satiety after meals, contributing to the average 14.9% body weight reduction observed in STEP-1 trials [1].

Mounjaro Appetite Suppression Timeline: What to Expect

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management [3]. By activating both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, Mounjaro produces more substantial metabolic effects than single-pathway treatments.

Appetite suppression with Mounjaro typically begins within 2 to 4 days of the first injection, slightly faster than semaglutide in clinical practice observations. The SURMOUNT-1 trial demonstrated that patients experienced significant reductions in hunger and food cravings within the first week, with progressive intensification as doses increased from 2.5mg to the maximum 15mg over 20 weeks [3].

Our clinical experience at Cured Pharmacy indicates that Mounjaro's dual-receptor mechanism produces particularly strong effects on post-meal satiety and between-meal hunger. Patients frequently report a notable absence of food-related thoughts and a natural reduction in snacking behaviour within the first month of treatment. The appetite-suppressing effects remain robust for 6 to 7 days after each injection, providing reliable week-long coverage [4].

Mounjaro Appetite Control: Dose Escalation Timeline

Week 1-4 (2.5mg dose): Early appetite reduction, with most patients noticing decreased hunger within 72 hours. Portion sizes typically reduce by 20-30%.

Week 5-8 (5mg dose): Substantial suppression of cravings and between-meal hunger. Many patients report forgetting to eat or losing interest in previously enjoyed foods.

Week 9-20 (7.5mg-15mg doses): Maximum appetite control achieved. Clinical trials showed patients at this stage experienced average body weight reductions of up to 22.5% over 72 weeks, partly attributable to sustained hunger suppression [3].

Wegovy vs Mounjaro: Direct Appetite Suppression Comparison

When comparing the wegovy vs mounjaro appetite suppression timeline, both medications demonstrate rapid onset of hunger control, but with subtle differences in intensity and duration. Mounjaro's dual-receptor mechanism typically produces slightly faster initial appetite reduction (2-4 days versus 3-5 days) and marginally longer duration between doses.

Head-to-head comparisons suggest that whilst Wegovy provides robust appetite suppression suitable for most patients, Mounjaro's dual-pathway action may offer superior hunger control in individuals who haven't achieved adequate results with GLP-1-only treatments [4]. The SURMOUNT trials showed greater reductions in body weight with tirzepatide compared to semaglutide, though both mechanisms effectively suppress appetite when properly dosed.

From a practical standpoint, the choice between Wegovy and Mounjaro often depends on individual response, medical history, and budget considerations. Wegovy starts from £124.99 at Cured Pharmacy, whilst Mounjaro is priced from £124.99 reflecting the newer dual-receptor technology. Both require prescription from a UK-registered prescriber following clinical assessment.

Which Treatment Offers Better Appetite Control?

Clinical trial data suggests Mounjaro produces slightly greater appetite suppression on average, particularly at higher doses, contributing to superior weight loss outcomes in the SURMOUNT studies [3]. However, individual responses vary considerably, and many patients achieve excellent appetite control and weight loss with Wegovy.

Our prescribing team at Cured Pharmacy evaluates multiple factors when recommending treatment, including your previous weight loss attempts, medication tolerance, budget, and specific appetite patterns. Subject to prescriber approval, either medication can provide effective hunger management when combined with dietary modifications and lifestyle changes.

Factors That Influence Appetite Suppression Timeline

Individual variation in appetite suppression timing is common with both Wegovy and Mounjaro. Factors affecting how quickly you experience hunger reduction include baseline metabolic rate, insulin sensitivity, gastric emptying speed, and previous exposure to GLP-1 treatments [2].

Patients with higher body mass index or significant insulin resistance may require longer to experience full appetite-suppressing effects, typically 2 to 3 weeks rather than days. Conversely, individuals who are treatment-naïve to GLP-1 receptor agonists often report more pronounced initial hunger suppression.

Adherence to the prescribed dose escalation schedule significantly impacts appetite control timeline. Skipping doses or inconsistent injection timing can delay the onset of hunger suppression and reduce overall effectiveness. Our clinical team recommends administering injections on the same day each week, at a time that aligns with your routine to maintain consistent appetite management throughout treatment.

Managing Appetite Suppression Side Effects

Whilst appetite suppression is the desired therapeutic effect, both Wegovy and Mounjaro can produce gastrointestinal side effects during the initial weeks of treatment. Nausea, reported in 20-44% of patients in clinical trials, typically peaks during dose escalation phases and diminishes as your body adapts [1][3].

To minimise nausea whilst maintaining appetite control, our pharmacists recommend eating smaller, more frequent meals rather than forcing large portions. Avoiding high-fat, spicy, or heavily processed foods during the first month can reduce gastric discomfort. Most patients find these side effects resolve within 4 to 6 weeks as tolerance develops.

If appetite suppression becomes excessive — leading to difficulty consuming adequate nutrition or persistent nausea — contact your prescriber immediately. Dose adjustments or temporary treatment pauses may be necessary to ensure safe, sustainable weight loss. All prescription treatments available through Cured Pharmacy include ongoing clinical support from UK-registered healthcare professionals.

Optimising Long-Term Appetite Control with Wegovy or Mounjaro

Sustaining appetite suppression over months and years requires more than medication alone. Clinical evidence demonstrates that patients who combine GLP-1 or dual-agonist treatments with structured dietary changes and regular physical activity achieve superior long-term outcomes [2][4].

As your body adapts to Wegovy or Mounjaro, some patients experience slight tolerance to appetite-suppressing effects after 6 to 12 months. Maintaining treatment adherence, staying adequately hydrated, and prioritising protein intake can help preserve hunger control throughout extended treatment courses.

At Cured Pharmacy, our UK-registered clinical team provides ongoing medication reviews to assess treatment effectiveness and adjust prescriptions as needed. Whether you're considering starting Wegovy from £135.00 or Mounjaro from £124.99 your journey begins with a free online consultation completed in under 3 minutes, followed by discreet delivery of genuine UK-licensed medications to your door.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
4. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on multiple factors including adherence to treatment, dietary modifications, and physical activity levels.